# EDGAR Filing Document

**Accession Number:** 0001386570
**File Stem:** 0001386570-26-000031
**Filing Date:** 2026-5
**Character Count:** 51701
**Document Hash:** bbb6a91a7f08ad0db3d8b7ce1c231c3a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001386570-26-000031.hdr.sgml**: 20260506

**ACCESSION NUMBER**: 0001386570-26-000031

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 35

**CONFORMED PERIOD OF REPORT**: 20260506

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260506

**DATE AS OF CHANGE**: 20260506

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Niagen Bioscience, Inc.
- **CENTRAL INDEX KEY:** 0001386570
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 262940963
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37752
- **FILM NUMBER:** 26948148

**BUSINESS ADDRESS:**
- **STREET 1:** 10900 WILSHIRE BLVD
- **STREET 2:** SUITE 600
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90024
- **BUSINESS PHONE:** 310-388-6706

**MAIL ADDRESS:**
- **STREET 1:** 10900 WILSHIRE BLVD
- **STREET 2:** SUITE 600
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90024

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ChromaDex Corp.
- **DATE OF NAME CHANGE:** 20080624

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CODY RESOURCES, INC.
- **DATE OF NAME CHANGE:** 20070112

?xml version='1.0' encoding='ASCII'? cdxc-20260506

  

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 6, 2026**![NIAGEN-Bioscience-Logo-Horizontal.jpg](cdxc-20260506_g1.jpg)

**NIAGEN BIOSCIENCE, INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-37752** | **26-2940963** |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

---

**10900 Wilshire Blvd. Suite 600, Los Angeles, California 90024**

(Address of principal executive offices, including zip code)

**(310) 388-6706**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.001 per share | NAGE | The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

  

------

**Item 2.02. Results of Operations and Financial Condition.**

On May 6, 2026, Niagen Bioscience, Inc. (the "Company") issued a press release announcing its earnings for the quarter ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1.

The information in this Item 2.02 and the exhibit hereto are being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, (the "Securities Act") or the Exchange Act, except as expressly set forth by specific reference in such filing.

**Item 7.01. Regulation FD Disclosure.**

On May 6, 2026, the Company released a corporate presentation which it made available on its website. A copy of the corporate presentation is attached hereto as Exhibit 99.2.

The information in this Item 7.01 and the exhibit hereto are being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Exhibits</u>.

---

| | |
|:---|:---|
| **Exhibit**<br>**Number** | **Description** |
| [99.1](ex991pressrelease-q12026.htm) | [Press Release dated](ex991pressrelease-q12026.htm)May 6, 2026 |
| [99.2](ex992earningspresentatio.htm) | [Earnings Presentation of Niagen Bioscience, Inc.](ex992earningspresentatio.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **NIAGEN BIOSCIENCE, INC.** | **NIAGEN BIOSCIENCE, INC.** |
| Dated: May 6, 2026 | By: | */s/ OZAN PAMIR* |
|  |  | Ozan Pamir |
|  |  | Chief Financial Officer |
|  |  | *(principal financial officer and duly authorized on behalf of the registrant)* |

---

## Exhibit 99.1

![niagen-biosciencexlogoxhora.jpg](niagen-biosciencexlogoxhora.jpg)

**Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results**

*Net sales increased to $31.5 million*

*Gross margin improved to 63.5%*

*Net income of $6.3 million, up $1.3 million from the prior year and adjusted EBITDA of $3.8 million*

**LOS ANGELES, CA - May 6, 2026 -** Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the first quarter of 2026.

**First Quarter 2026 Financial Highlights**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Total net sales increased 3% to $31.5 million, including $22.4 million from Tru Niagen®. Excluding the recently sold Analytical Reference Standards and Services segment from both periods, net sales rose 5% to $31.1 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Gross margin of 63.5%, reflecting continued strength in business mix.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net income of $6.3 million, including a $4.8 million gain on the divestiture of the Analytical Reference Standards and Services operating segment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Basic and diluted earnings per share were $0.08 and $0.07, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA, a non-GAAP measure, was $3.8 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Working capital<sup>(1)</sup> increased by $5.4 million quarter-over-quarter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Used $1.2 million in operating cash flow during the quarter, driven by increased inventory levels and timing of receivables, ending with $66.5 million in cash and cash equivalents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Repurchased $2.4 million of common stock during the quarter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Updated full year 2026 outlook: Sales & marketing investment expected to increase; general & administrative expense outlook improved to up $3–$4 million (from $4–$5 million).

**Recent Operational Highlights**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In May 2026, the Company launched a clinician-directed telehealth platform under Niagen Plus, enabling eligible U.S. patients to access prescription-based Niagen® at-home injection kits, expanding the Niagen Plus clinic channel beyond in-person settings and introducing a direct-to-patient access model.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In April 2026, the Company announced the establishment of the first United States Pharmacopeia (USP) monograph for nicotinamide riboside chloride (NRCL), supported by the Company's scientific analytical contributions, establishing a standardized quality benchmark for NR-based ingredients and reinforcing the Company's leadership in NAD+ science and quality.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In April 2026, the Company announced the addition of another 503B compounding partner, diversifying the Company's 503B network and supply chain capabilities while expanding Niagen Plus to include new product offerings.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In March 2026, the Company expanded the Niagen Plus clinical channel with its first cruise ship clinic partnership, enabling the availability of Niagen IV across more than 80 Medi-Spa clinics operated by OneSpaWorld aboard high-end cruise ships, further extending access through premium medical and wellness channels.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In March 2026, the Company's board of directors approved an increase of the Company's share repurchase program to $20 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In March 2026, the Company entered the skincare category through the launch of Niagen's Nanocloud™, a topical product developed by the Niagen Skincare Innovation Lab, to evaluate market opportunity and generate consumer insights to guide future development.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In February 2026, the Company completed the divestiture of the Analytical Reference Standards and Services operating segment to LGC Standards in an all-cash transaction, further streamlining operations and reinforcing its focus on core NAD+ science and commercial growth.

"We delivered $31.5 million of net sales and $6.3 million of net income for the first quarter," said Niagen Bioscience CEO, Rob Fried. "Our results reflect continued execution across the business, including growth in our e-commerce channel and progress across key strategic initiatives. We are advancing our scientific leadership and expanding our commercial reach while remaining focused on disciplined investment and long-term value creation from our NAD+ platform."

(1) Working capital is defined as current assets minus current liabilities in each period. Prior disclosures referenced operating working capital (accounts receivable, inventory, and accounts payable). The definition was updated in the current period to align with standard financial statement presentation and improve comparability.

![niagen-biosciencexlogoxicona.jpg](niagen-biosciencexlogoxicona.jpg)

------

**Results of operations for the three months ended March 31, 2026 compared to the prior year quarter** 

**Net Sales** increased to $31.5 million. Excluding the impact of the divested segment in both periods, net sales increased approximately 5% year-over-year. The growth in net sales was driven by continued growth in Tru Niagen®, led by strong e-commerce performance and higher sales through different distribution channels, partially offset by variability in orders from A.S. Watson. Niagen® ingredient sales also contributed to the growth.

**Gross Margin** improving to 63.5%, reflecting favorable business mix and supply chain efficiencies.

**Operating Expense** increased 26%, or $3.8 million, to $18.4 million, reflecting planned investments to support brand growth and commercial activities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**•** Sales and marketing expense increased $1.6 million, driven by higher advertising and marketing spend to support consumer brand growth initiatives.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**•** General and administrative expense increased $2.1 million, primarily due to the absence of a prior year credit loss recovery and higher share-based compensation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Research and development expenses increased $0.2 million, reflecting continued investment in Niagen Plus research activities and research for therapeutic development.

**Net Income** was $6.3 million compared to $5.1 million for the first quarter of 2025.

**Basic and Diluted Earnings Per Share** were $0.08 and $0.07, respectively, compared to $0.07 basic earnings per share and $0.06 diluted earnings per share in the prior year quarter.

**Adjusted EBITDA,** a non-GAAP measure, was $3.8 million compared to $4.9 million for the first quarter of 2025. See "Reconciliation of Non-GAAP Financial Measures" for a reconciliation of non-GAAP Adjusted EBITDA to net income, the most directly comparable GAAP measure.

**Cash Flows from Operating Activities** had a net cash outflow of $1.2 million for the three months ended March 31, 2026, primarily driven by increases in inventory and trade receivables, including timing of customer collections, partially offset by net income adjusted for non-cash items, including the gain on the sale of the Analytical Reference Standards and Services operating segment.

**2026 Full Year Outlook**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ **Net sales**: Increasing between 10-15% year-over-year excluding 2025 net sales attributable to the Analytical Reference Standards and Services segment, driven primarily by e-commerce business and new strategic partnerships.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ **Gross margin**: Slight improvement year-over-year, driven by improvements in inventory cost and product mix.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ **Sales & marketing**: Increasing in absolute dollars and as a percentage of sales, driven by increased investments to drive customer acquisition and support the launch of new verticals (compared to the previous guidance of stable as a percentage of sales).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ **Research & development**: Increasing, driven by investment into pharmaceutical development and continued research initiatives related to topical and injection applications.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ **General & administrative**: $3 million to $4 million increase driven by infrastructure investments and legal expenses to support the growth of existing business and new market launches, as well as increased share-based compensation expense with the absence of credit loss recovery.

![niagen-biosciencexlogoxicona.jpg](niagen-biosciencexlogoxicona.jpg)

------

**Investor Conference Call**

A live webcast will be held Wednesday, May 6, 2026 at 4:30 p.m. Eastern Daylight Time (1:30 p.m. Pacific Daylight Time) to discuss Niagen Bioscience's first-quarter financial results and provide a general business update.

To listen to the webcast, or to view the earnings press release and its accompanying financial exhibits, please visit the Investors Relations section of Niagen Bioscience's website at https://investors.niagenbioscience.com. The toll-free dial-in information for this call is 1-833-461-5787 with Conference ID: 828848803.

The webcast will be recorded, and will be available for replay via the website from 7:30 p.m. Eastern Daylight Time on May 6, 2026 through 11:59 p.m. Eastern Daylight Time on May 6, 2027. The replay of the call can also be accessed by dialing 1-833-461-5787, using the Replay ID: 828848803.

**Important Note on Forward Looking Statements:**

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes" "seeks," "may," "will," "should," "could," "predicts," "projects," "continues," "would" or the negative of such terms or other similar expressions. Forward-looking statements include without limitation, statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the quotation from Niagen Bioscience's Chief Executive Officer, statements related to the Company's 2026 financial outlook including but not limited to net sales growth, gross margin, expenses, investment priorities, and commercialization efforts and statements regarding Niagen® and Niagen Plus® clinical initiatives and statements attributable to management.

Risks that contribute to the uncertain nature of the forward-looking statements include: our relationships with major customers; a decline in general economic conditions nationally and internationally; the market and size of the vitamin, mineral and dietary supplement market and the intravenous market; decreased demand for our products and services; market acceptance of our products; the ability to protect our intellectual property rights; impact of any litigation or infringement actions brought against us; competition from other providers and products; risks in product development; our ability to develop pharmaceutical business; inability to raise capital to fund continuing operations or new product development; changes in government regulation or regulatory priorities of government officials; the ability to complete customer transactions and capital raising transactions; inflationary conditions and adverse economic conditions; our history of operating losses; the growth and profitability of our product sales; our ability to maintain and grow sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; risks of conducting business in China; unanticipated developments in and risks related to the Company's ability to secure adequate quantities of pharmaceutical-grade Niagen in a timely manner; the Company's ability to obtain appropriate contracts and arrangements with U.S. FDA-registered 503B outsourcing facilities required to compound and distribute pharmaceutical-grade Niagen to clinics; the Company's ability to remain on the U.S. FDA Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Category 1 list; the Company's ability to maintain and enforce the Company's existing intellectual property and obtain new patents; whether the potential benefits of NRC can be further supported; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA and other governmental authorities, including with respect to products seeking to compete in our market; mislabeling or other misleading marketing practices by competitors; economic and market instability, including as a result of tariffs or trade conflicts; and the risks and uncertainties associated with our business and financial condition in general, described in our filings with the Securities and Exchange Commission (SEC), including, without limitation, our most recent Annual Report on Form 10-K as filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and Niagen Bioscience undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

![niagen-biosciencexlogoxicona.jpg](niagen-biosciencexlogoxicona.jpg)

------

**About Niagen Bioscience, Inc.:**

Niagen Bioscience is a global bioscience company focused on healthy aging. The Company is a leader in research on NAD+ (nicotinamide adenine dinucleotide), an essential coenzyme that supports cellular metabolism and declines with age. Niagen Bioscience is the innovator of nicotinamide riboside chloride ("NRC" or "NRCL," commonly referred to as "NR"), a patented NAD+ precursor commercialized as Niagen®, available in both food-grade and pharmaceutical-grade forms. Nicotinamide riboside chloride and other NAD+ precursors are protected by Niagen Bioscience's patent portfolio.

The Company markets its consumer supplement Tru Niagen® and develops and supplies Niagen® as a proprietary ingredient to partners across the health and wellness and pharmaceutical sectors. Niagen Bioscience is also advancing research and development of NAD+ precursor-based technologies for potential therapeutic applications. Follow us on X (formerly Twitter) @NiagenBio and Instagram @TruNiagen and @NiagenPlus and subscribe to our latest news via our website accessible at www.NiagenBioscience.com to which Niagen Bioscience regularly posts copies of its press releases as well as additional updates and financial information about the Company.

**Contacts:** 

---

| |
|:---|
| **Investor Relations** |
| KCSA Strategic Communications |
| Valter Pinto, Managing Director |
| 1 (212) 896-1254 |
| <u>Niagen@kcsa.com</u> |
| **Media Relations** |
| Kendall Knysch |
| Senior Director of Media Relations & Partnerships |
| +1 (310) 405-5227 |
| <u>Kendall.Knysch@NiagenBio.com</u> |

---

![niagen-biosciencexlogoxicona.jpg](niagen-biosciencexlogoxicona.jpg)

------

**Niagen Bioscience, Inc. and Subsidiaries**

**Unaudited Condensed Consolidated Statements of Operations**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| *(In thousands, except per share data)* |  |  |
| Sales, net | $**31474** | $30481 |
| Cost of sales | **11498** | 11150 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross profit | **19976** | 19331 |
| Operating expenses: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales and marketing | **9675** | 8117 |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | **1481** | 1258 |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative | **7244** | 5184 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | **18400** | 14559 |
| Operating income | **1576** | 4772 |
| Nonoperating income: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income, net | **375** | 459 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on sale of operating segment | **4784** |  |
| Income before provision for income taxes | **6735** | 5231 |
| Provision for income taxes | **417** | 168 |
| Net income | $**6318** | $5063 |
| Net income per share attributable to common stockholders: |  |  |
| Basic | $**0.08** | $0.07 |
| Diluted | $**0.07** | $0.06 |
| Weighted average common shares outstanding: |  |  |
| Basic | **79917** | 77810 |
| Diluted | **84566** | 83232 |

---

![niagen-biosciencexlogoxicona.jpg](niagen-biosciencexlogoxicona.jpg)

------

**Niagen Bioscience, Inc. and Subsidiaries**

**Unaudited Condensed Consolidated Balance Sheets**

---

| | | |
|:---|:---|:---|
| *(In thousands)* | **March 31, 2026** | **December 31, 2025** |
| **Assets** |  |  |
| Current assets: |  |  |
| &nbsp;&nbsp;Cash and cash equivalents, including restricted cash of $152 for both periods presented | $**66549** | $64788 |
| &nbsp;&nbsp;Trade receivables, net of allowances of $176 and $147, respectively | **13068** | 9741 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories | **24016** | 20424 |
| &nbsp;&nbsp;&nbsp;&nbsp;Assets held for sale | **—** | 541 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other assets | **1488** | 1312 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | **105121** | 96806 |
| Leasehold improvements and equipment, net | **1298** | 1323 |
| Intangible assets, net | **5485** | 5660 |
| Right-of-use assets, net | **2019** | 2192 |
| Other long-term assets | **406** | 425 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $**114329** | $106406 |
| **Liabilities and Stockholders' Equity** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;Accounts payable | $**13277** | $10796 |
| &nbsp;&nbsp;Accrued expenses | **7621** | 7722 |
| &nbsp;&nbsp;Current maturities of operating lease obligations | **1032** | 1002 |
| &nbsp;&nbsp;Current deferred consideration liability | **514** |  |
| &nbsp;&nbsp;Customer deposits | **380** | 399 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | **22824** | 19919 |
| Deferred revenue | **2572** | 2674 |
| Operating lease obligations, less current maturities | **1544** | 1815 |
| Deferred consideration liability, less current portion | **5059** | 5465 |
| Total stockholders' equity | **82330** | 76533 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' equity | $**114329** | $106406 |

---

**Niagen Bioscience, Inc. and Subsidiaries**

**Unaudited Condensed Consolidated Statements of Cash Flows**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|<br>*(In thousands)* | **2026** | **2025** |
| **Net cash provided by / (used in):** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating activities | $**(1194)** | $7883 |
| &nbsp;&nbsp;&nbsp;&nbsp;Investing activities | **5245** | (32) |
| &nbsp;&nbsp;&nbsp;&nbsp;Financing activities | **(2290)** | 3105 |
| Net increase in cash and cash equivalents | **1761** | 10956 |
| Cash and cash equivalents beginning of period | **64788** | 44660 |
| Cash and cash equivalents at end of period | $**66549** | $55616 |

---

![niagen-biosciencexlogoxicona.jpg](niagen-biosciencexlogoxicona.jpg)

------

**Niagen Bioscience, Inc. and Subsidiaries**

**Unaudited Reconciliation of Non-GAAP Financial Measures**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Reconciliation of Net Income to Adjusted EBITDA** | **Reconciliation of Net Income to Adjusted EBITDA** | **Reconciliation of Net Income to Adjusted EBITDA** | **Reconciliation of Net Income to Adjusted EBITDA** | **Reconciliation of Net Income to Adjusted EBITDA** | **Reconciliation of Net Income to Adjusted EBITDA** |
| *(In thousands)* | **Q1 2026** | **Q4 2025** | **Q3 2025** | **Q2 2025** | **Q1 2025** |
| Net income, as reported | $**6318** | $4132 | $4578 | $3609 | $5063 |
| *Adjustments:* |  |  |  |  |  |
| &nbsp;&nbsp;Interest income, net | **(375)** | (552) | (564) | (552) | (459) |
| &nbsp;&nbsp;Provision for income taxes | **417** | 292 | 222 | 128 | 168 |
| &nbsp;&nbsp;Depreciation | **116** | 139 | 157 | 158 | 158 |
| &nbsp;&nbsp;Amortization of intangibles | **175** | 60 | 38 | 38 | 37 |
| &nbsp;&nbsp;Noncash lease expense | **173** | 169 | 164 | 159 | 173 |
| &nbsp;&nbsp;Share-based compensation | **1716** | 1748 | 1756 | 1488 | 1075 |
| &nbsp;&nbsp;Severance and restructuring | **79** | 53 | 10 | 21 | 4 |
| &nbsp;&nbsp;Gain on settlement of royalty obligation (1) | **—** | (1983) |  |  |  |
| &nbsp;&nbsp;Recovery of credit losses related to legal settlement (2) | **—** |  |  |  | (1325) |
| &nbsp;&nbsp;Gain on sale of operating segment (3) | **(4784)** |  |  |  |  |
| Adjusted EBITDA | $**3835** | $4058 | $6361 | $5049 | $4894 |

---

(1) Represents a gain related to the settlement of royalty obligations from a settlement agreement with Queen's University of Belfast.

(2) Represents the recovery of previously recognized credit losses related to the legal settlement with Elysium Health, LLC in 2024.

(3) Represents a gain related to the sale of the Company's Analytical Reference Standards and Services operating segment.

**Non-GAAP Financial Information:**

To supplement Niagen Bioscience's unaudited financial data presented in accordance with generally accepted accounting principles (GAAP), the Company has presented Adjusted EBITDA, a non-GAAP financial measure. Niagen Bioscience believes the presentation of this non-GAAP financial measure provides important supplemental information to management and investors and enhances the overall understanding of the Company's historical and current financial operating performance. The Company believes disclosure of the non-GAAP financial measure has substance because the excluded expenses are infrequent in nature, are variable in nature or do not represent current cash expenditures. Further, such non-GAAP financial measure is among the indicators the Company uses as a basis for evaluating the Company's financial performance as well as for planning and forecasting purposes. Accordingly, disclosure of this non-GAAP financial measure provides investors with the same information that management uses to understand the Company's economic performance year-over-year.

Adjusted EBITDA is defined as net income before (a) interest, (b) provision for income taxes, (c) depreciation, (d) amortization, (e) non-cash share-based compensation costs, (f) severance and restructuring expense and (g) other infrequent items, including gains recognized related to the sale of an operating segment and a royalty settlement, as well as the recovery of previously recognized credit losses from a legal settlement. While Niagen Bioscience believes that this non-GAAP financial measure provides useful supplemental information to investors, there are limitations associated with the use of such measure. This measure is not prepared in accordance with GAAP and may not be directly comparable to similarly titled measures of other companies due to potential differences in the method of calculation. Management compensates for these limitations by relying primarily on the Company's GAAP results and by using Adjusted EBITDA only supplementally and by reviewing the reconciliation of the non-GAAP financial measure to its most comparable GAAP financial measure.

Non-GAAP financial measures are not prepared in accordance with, or an alternative for, generally accepted accounting principles in the United States. The Company's non-GAAP financial measure is not meant to be considered in isolation or as a substitute for comparable GAAP financial measures and should be read only in conjunction with the Company's consolidated financial statements prepared in accordance with GAAP.

![niagen-biosciencexlogoxicona.jpg](niagen-biosciencexlogoxicona.jpg)

## Exhibit 99.2

![](ex992earningspresentatio001.jpg)

Niagen Bioscience, Inc. Earnings Presentation First Quarter 2026 Nasdaq: NAGE \| May 6, 2026

------

![](ex992earningspresentatio002.jpg)

2 This presentation and other written or oral statements made from time to time by representatives of Niagen Bioscience contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements reflect the current view about future events. Statements that are not historical in nature, such as 2026 financial outlook, and which may be identified by the use of words like "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could," "predicts," "projects," "continue," "would" or the negative of these terms and other words of similar meaning, are forward-looking statements. Such statements include, but are not limited to, statements contained in this presentation relating to our expected sales, cash flows, planned investments, and financial performance, business, business strategy, expansion, growth, key drivers (including cost savings and increased investments), products and services we offer and their impact on our performance or products and services we may offer in the future and the timing of their development, sales and marketing strategy and capital outlook. Forward-looking statements are based on management's current expectations and assumptions regarding our business, the economy and other future conditions and are subject to inherent risks, uncertainties and changes of circumstances that are difficult to predict and may cause actual results to differ materially from those contemplated or expressed. We caution you therefore against relying on any of these forward-looking statements. These risks and uncertainties include those risk factors discussed in Part I, "Item 1A. Risk Factors" of our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities Exchange Commission (the "Commission"), and in subsequent filings with the Commission. Any forward-looking statements are qualified in their entirety by reference to the factors discussed in these filings with the Commission. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned. Important factors that could cause actual results to differ materially from those in the forward looking statements include but are not limited to: our relationships with major customers; a decline in general economic conditions nationally and internationally; the market and size of the vitamin mineral and dietary supplement market and the intravenous market; decreased demand for our products and services; market acceptance of our products; the ability to protect our intellectual property rights; impact of any litigation or infringement actions brought against us; competition from other providers and products; risks in product development; our ability to develop pharmaceutical business; inability to raise capital to fund continuing operations or new product development; changes in government regulation or regulatory priorities of government officials; the ability to complete customer transactions and capital raising transactions; inflationary conditions and adverse economic conditions; our history of operating losses; the growth and profitability of our product sales; our ability to maintain and grow sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; risks of conducting business in China; unanticipated developments in and risks related to the Company's ability to secure adequate quantities of pharmaceutical-grade Niagen in a timely manner; the Company's ability to obtain appropriate contracts and arrangements with U.S. FDA-registered 503B outsourcing facilities required to compound and distribute pharmaceutical-grade Niagen to clinics; the Company's ability to remain on the U.S. FDA Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Category 1 list; the Company's ability to maintain and enforce the Company's existing intellectual property and obtain new patents; whether the potential benefits of NRC can be further supported; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA and other governmental authorities, including with respect to products seeking to compete in our market; mislabeling or other misleading marketing practices by competitors; economic and market instability, including as a result of tariffs or trade conflicts; and the risks and uncertainties associated with our business and financial condition in general. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results. About Non-GAAP Financial Measures Niagen Bioscience's non-GAAP financial measure, Adjusted EBITDA, is defined as net income before interest, provision for income taxes, depreciation, amortization, non-cash share-based compensation costs, severance and restructuring expense and other infrequent items, including gains recognized related to the sale of an operating segment and a royalty settlement, as well as the recovery of previously recognized credit losses from a legal settlement. Niagen Bioscience used this non-GAAP measures when evaluating its financial results as well as for internal resource management, planning and forecasting purposes. This non-GAAP measure should not be viewed in isolation from or as a substitute for Niagen Bioscience's financial results in accordance with GAAP. Reconciliation of this non-GAAP measure to the most directly comparable GAAP measure is attached to this presentation. FDA Disclaimer Statements made in this presentation have not been evaluated by the Food and Drug Administration. Niagen Bioscience products are not intended to diagnose, treat, cure, or prevent any disease. The statements in this presentation are for investor relations and educational purposes only and not intended for consumers or vendors. Safe Harbor Statement

------

![](ex992earningspresentatio003.jpg)

**Table of Contents** & Leadership Team 3 Rob Fried Chief Executive Officer Carlos Lopez SVP, General Counsel Andrew Shao SVP, Global Regulatory & Scientific Affairs Michiko Kelley Chief Marketing Officer 1. Highlights 2. Financial Results & Outlook 3.Scientific Updates 4.Contact Information Ozan Pamir Chief Financial Officer

------

![](ex992earningspresentatio004.jpg)

(1) See slide 12 for the non-GAAP reconciliation 4 63.5% gross profit margin Diluted EPS of $0.07 $6.3 million net income $3.8 million Adjusted EBITDA(1) $66.5 million cash, no outstanding borrowings First Quarter 2026 Highlights $31.5 million net sales

------

![](ex992earningspresentatio005.jpg)

Enterprise • Completed divestiture of Analytical Reference Standards and Services operating segment in an all-cash transaction, further streamlining operations and reinforcing focus on core NAD+ science and commercial growth • Board of directors approved an increase to the share repurchase program to $20 million and the Company repurchased $2.4 million of shares during the quarter Tru Niagen and Niagen Ingredient • Launched Niagen Skincare Innovation Lab and limited-release topical skincare product, Niagen NanoCloud™, to generate consumer insight and shape future topical innovation • Expanded the Niagen Plus™ channel with the Company's first cruise ship clinic partnership, enabling the availability of Niagen IV across more than 80 Medi-Spa clinics operated by OneSpaWorld aboard high- end cruise ships Science • Expanded external research program to more than 300 material transfer agreements with over 200 institutions globally, reinforcing breadth of independent scientific research supporting Niagen® Operational Execution Supported Q1 2026 Performance 5

------

![](ex992earningspresentatio006.jpg)

Performance Driven by Strong E-Commerce Performance 6 Q1 2026 Net Sales Q1 2026 Y/Y Growth Takeaways Total Niagen Bioscience $31.5M 3% • Excluding the impact of the divested segment in both periods, net sales increased approximately 5% YoY Tru Niagen $22.4M 4% • Consistent E-commerce performance delivering 14% growth • Impacted by lower sales to A.S. Watson, partially offset by higher sales with other distributor partners Niagen Ingredient $8.2M 2% • Higher sales to food-grade ingredient partners, partially offset by lower pharmaceutical-grade Niagen sales Positioned for What's Next: We remain focused on executing our strategy, investing in key growth drivers and capturing long- term opportunities across core channels.

------

![](ex992earningspresentatio007.jpg)

Q1 2026: Continued Profitability and Disciplined Operations (1) See slide 12 for the non-GAAP reconciliation. 7 Net Sales Q1 2026 +3% YoY Tru Niagen +4% Gross Margin Q1 2026 63.5% +10 bps Net Income Q1 2026 $6.3M Adj. EBITDA(1) $3.8M Cash & Liquidity YTD 2026 Cash used for Operations: $1.2M Quarter-End Cash: $66.5M Outstanding Borrowings: None 2026 Outlook (Updated) • Net sales growth reaffirmed at 10-15%, excluding divested operating segment in both years • G&A expense improved to up $3–$4 million (from $4–$5 million) • Continued strategic brand investment and commercial activities • Focus on NAD precursor innovation and development Delivered across net sales, profitability, and cash flow

------

![](ex992earningspresentatio008.jpg)

The information contained in this documents is confidential, privileged and only for the information of the intended recipient and may not be used, published or redistributed without the prior written consent (2019) Financial Highlights

------

![](ex992earningspresentatio009.jpg)

Q1 2026 Net Sales: $31.5M (+3% YoY) 9 Q1 2026 Q1 2025 Tru Niagen $22.4M $21.5M E-Commerce $19.2M $16.8M Watson's & Other B2B $3.2M $4.7M Niagen Ingredients $8.2M $8.0M Food-grade Niagen® $7.3M $7.0M Pharmaceutical-grade Niagen® $0.9M $1.0M Other Ingredients $0.4M $0.2M Analytical Reference Standards & Services(1) $0.4M $0.8M Corporate and Other(2) $0.1M $0.0M $30.5M $31.5M Q1 2025 Q1 2026 56% 15% 23% +3% 61% 10% 23% (1) In February 2026, the Company divested its Analytical Reference Standards and Services operating segment. (2) Beginning March 2026 includes net sales from the transition services agreement (TSA) related to the disposition of the operating segment. TSA revenue is expected to continue only through the agreement's anticipated completion in Q3 2026. Total Company: $29.7M $31.1M Q1 2025 Q1 2026 56% 15% 23% +5% 61% 10% 23% Total Company, excluding divested segment:

------

![](ex992earningspresentatio010.jpg)

2025 – 2026 Net Sales Summary 10 ($ in millions) 2026 2025 Q1 Q1 Q2 Q3 Q4 FY Ecommerce 19.2 16.8 18.1 19.0 20.2 74.1 Watson's & Other B2B 3.2 4.7 4.6 7.0 7.3 23.6 Total Tru Niagen 22.4 21.5 22.7 26.0 27.5 97.7 Food-grade Niagen 7.3 7.0 6.0 6.4 4.7 24.1 Pharmaceutical-grade Niagen 0.9 1.0 1.4 0.5 0.9 3.8 Total Niagen Ingredient 8.2 8.0 7.4 6.9 5.6 27.9 Niagen Related Revenues 30.6 29.5 30.1 32.9 33.1 125.6 Other Ingredients 0.4 0.2 0.2 0.3 0.0 0.7 Analytical Reference Standards & Services(1) 0.4 0.8 0.8 0.8 0.7 3.1 Corporate and Other(2) 0.1 0.0 0.0 0.0 0.0 0.0 Total Net Sales 31.5 30.5 31.1 34.0 33.8 129.4 Total Net Sales, Excluding Divested Segment 31.1 29.7 30.3 33.2 33.1 126.3 Tru Niagen as % of Total Net Sales 71 % 71 % 73 % 77 % 81 % 75 % Niagen Related Revenues as % of Total Net Sales 97 % 97 % 97 % 97 % 98 % 97 % YoY Growth Rate - Net Sales Total Company 3 % 38 % 37 % 33 % 16 % 30 % Niagen Related 4 % 37 % 38 % 33 % 18 % 31 % Total Tru Niagen 4 % 24 % 22 % 44 % 21 % 27 % (1) In February 2026, the Company divested its Analytical Reference Standards and Services operating segment. (2) Beginning March 2026 includes net sales from the transition services agreement (TSA) related to the disposition of the operating segment. TSA revenue is expected to continue only through the agreement's anticipated completion in Q3 2026.

------

![](ex992earningspresentatio011.jpg)

Three Months Ended March 31, ($ in thousands) 2026 2025 Net Sales 31,474 30,481 Gross Profit % of Net Sales 19,976 63.5% 19,331 63.4% Sales and Marketing % of Net Sales 9,675 30.7% 8,117 26.6% Research and Development 1,481 1,258 General and Administrative (1) 7,244 5,184 Operating Income 1,576 4,772 Nonoperating - Gain on Sale of Operating Segment (2) 4,784 — Net Income 6,318 5,063 Adjusted EBITDA (3) 3,835 4,894 Key P&L Metrics 11 (1) G&A in Q1 2025 was reduced by a $1.3 million recovery of prior credit losses related to the Elysium Health legal settlement. (2) Reflects the gain on sale related to the divestiture of the analytical reference standards and services operating segment in February 2026. (3) See slide 12 for the non-GAAP reconciliation.

------

![](ex992earningspresentatio012.jpg)

Adjusted EBITDA Summary Adjusted EBITDA was $3.8 million in Q1 2026, reflecting underlying operating performance, with non-core divestiture gains excluded. 12 Reconciliation of Non-GAAP Financial Measures (In thousands) Three Months Ended FY 2025 Three Months Ended Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Net income, as reported $5,063 $3,609 $4,578 $4,132 $17,382 $6,318 Adjustments Interest income, net (459) (552) (564) (552) (2,127) (375) Provision for income taxes 168 128 222 292 810 417 Depreciation 158 158 157 139 612 116 Amortization of intangibles 37 38 38 60 173 175 Noncash lease expense 173 159 164 169 665 173 Share-based compensation 1,075 1,488 1,756 1,748 6,067 1,716 Severance and restructuring 4 21 10 53 88 79 Gain on settlement of royalty obligation (1) — — — (1,983) (1,983) — Recovery of credit losses related to legal settlement (2) (1,325) — — — (1,325) — Gain on sale of operating segment (3) — — — — — (4,784) Adjusted EBITDA $4,894 $5,049 $6,361 $4,058 $20,362 $3,835 (1) Gain recognized related to the settlement of royalty obligations from an agreement with Queen's University of Belfast. (2) The recovery of credit losses stems from the 2024 legal settlement with Elysium Health, LLC, paid in two installments, reversing a bad debt write-off from 2019. (3) Gain related to the sale of the Company's Analytical Reference Standards and Services operating segment.

------

![](ex992earningspresentatio013.jpg)

Strong balance sheet allowing financial and operational flexibility. Quarterly Balance Sheet Highlights (in thousands) 3/31/25 6/30/25 9/30/25 12/31/25 3/31/26 Key Drivers (Q4 2025 vs Q1 2026) Cash $55,616 $60,474 $64,290 $64,788 $66,549 Up $1.8 million primarily driven by net income and proceeds from the sale of non-core business, partially offset by share repurchases Inventory 11,185 14,406 18,791 20,424 24,016 Up $3.6 million to scale inventory to support business growth and planned commercial activities, representing a peak level with normalization expected through the remainder of the year Trade Receivables 7,052 9,656 8,506 9,741 13,068 Up $3.3 million driven by modestly higher sales and collection timing, including a $1.3 million receivable collected in April and a temporary impact from Amazon reserve holdbacks Accrued Liabilities 9,050 7,381 8,700 7,722 7,621 Down $0.1 million driven by changes in and timing of expenses, consistent with historic trends Accounts Payable 10,632 13,680 12,742 10,796 13,277 Up $2.5 million driven by increased inventory purchases and timing of disbursements Equity $55,345 $64,195 $70,676 $76,533 $82,330 Up $5.8 million driven by net income, share-based compensation and proceeds from stock option exercises, partially offset by share repurchases 13

------

![](ex992earningspresentatio014.jpg)

14 Cash Flow Highlights Three Months Ended FY 2025 Three Months Ended (in thousands) 3/31/25 6/30/25 9/30/25 12/31/25 3/31/26 Net Income $5,063 $3,609 $4,578 $4,132 $17,382 $6,318 Working Capital 2,681 (4,399) (3,004) (3,669) (8,391) (5,017) Cash From / (Used for) Operations 7,883 1,250 3,692 679 13,504 (1,194) Cash From / (Used for) for Investing (32) (135) (24) (101) (292) 5,245 Cash From / (Used for) Financing 3,105 (1) 3,743 (2) 148 (3) (80) (4) 6,916 (5) (2,290) (6) Net Increase in Cash $10,956 $4,858 $3,816 $498 $20,128 $1,761 Ending Cash Balance $55,616 $60,474 $64,290 $64,788 $64,788 $66,549 Strategic investments during the quarter to support core operations and execute share repurchases, partially offset by gains from the sale of non-core operating segment. 1. Includes $3.1 million in proceeds from the exercise of stock options. 2. Includes $3.7 million in proceeds from the exercise of stock options. 3. Includes $0.2 million in proceeds from the exercise of stock options. 4. Includes $0.2 million in proceeds from the exercise of stock options and ($0.3) million in repurchase of common stock 5. Includes $7.2 million in proceeds from the exercise of stock options and ($0.3) million in repurchase of common stock. 6. Includes $0.1 million in proceeds from the exercise of stock options and ($2.4) million in repurchase of common stock.

------

![](ex992earningspresentatio015.jpg)

Continued momentum in net sales, supported by strategic investments to strengthen brand and foster scientific innovation while maintaining operational efficiency. 2026 Financial Outlook 15(1) FY 2025 actual G&A includes the recovery of approximately $1.3 million in credit losses related to the legal settlement with Elysium Health, LLC. 2025 Actual ($ in thousands) 2026 Full Year Outlook Key Drivers Net Sales (Net sales, excluding divested segment) $129,423 ($126,347) Increasing between 10-15% Y/Y (excluding Analytical Reference Standards and Services segment) • Includes growth from E-commerce business and recurring net sales from established partnerships • Includes net sales from new B2B partnerships and sales channels Gross Margin % 64.3% Slight improvement Y/Y • Includes continued scaling of favorable product mix • Includes benefit from lower-cost inventory sales Sales & Marketing $35,506 Up in absolute dollars and as a % of net sales Y/Y (vs 27.4% of net sales in FY 2025) • Strategic investments to drive customer acquisition and retention while enhancing marketing efficiencies • Includes targeted investments to support the launch of new verticals Research & Development $6,330 Up in absolute dollars Y/Y • Includes investments into pharmaceutical development and external research in order to support new product development and innovation General & Administrative(1) $27,057 Up $3.0 to $4.0 million in absolute dollars Y/Y • Includes infrastructure and legal investments to support scalable growth • Increased share-based compensation expense.

------

![](ex992earningspresentatio016.jpg)

The information contained in this documents is confidential, privileged and only for the information of the intended recipient and may not be used, published or redistributed without the prior written consent (2019) 16 The Science

------

![](ex992earningspresentatio017.jpg)

Scientific Advisory Board 17

------

![](ex992earningspresentatio018.jpg)

18 Clinical Studies on Oral Niagen® in Multiple Health Areas Note: Highlighted achievements in duration, participation, and dosage only consider peer-reviewed, published studies. Status of clinical studies presented as of April 24, 2026.

------

![](ex992earningspresentatio019.jpg)

The information contained in this documents is confidential, privileged and only for the information of the intended recipient and may not be used, published or redistributed without the prior written consent (2019) 19 Contact Info: Niagen Bioscience Investor Relations: KCSA Strategic Communications Valter Pinto, Managing Director T: +1 (212) 896-1254 Niagen@kcsa.com www.niagenbioscience.com Where to purchase Tru Niagen® TruNiagen.com Find Health Clinics Offering Niagen® Plus NiagenPlus.com

------